Resultados de la búsqueda 61-70 of 3056 for Proto-oncogene

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study Of The Drugs Selumetinib Vs. Carboplatin And Vincristine In Patients With Low-Grade Glioma. Rochester, Minn. This study aims to demonstrate that the ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic. The purpose of the registry will be to support ongoing ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Create a registry of patients having or at risk for cancer of the liver or bile ducts (also known as hepatocellular carcinoma or cholangiocarcinoma), or ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

  7. Estar en forma - Mayo Clinic

    News. septiembre 2024. Perimenopause, menopause and ... weightlifting? Expert explains value for bone health Sept. 04, 2024, 03:15 p.m. CDT ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...